(2S,3R,4S,5R)-3,4,5,6-tetrahydroxy-2-(methylamino)hexanal

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2S,3R,4S,5R)-3,4,5,6-tetrahydroxy-2-(methylamino)hexanal
• 化学式: C₇H₁₅NO₅
• 分子量: 193.2
• InChiKey: LDDMACCNBZAMSG-DBRKOABJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.2
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  110
• 氢给体数：
  5
• 氢受体数：
  6

文献信息

• GLYCERO-COMPOUND HAVING TRIPLE BOND AND MEMBRANE MATERIAL CONTAINING THE SAME
  申请人：BABA Teruhiko

  公开号：US20070105823A1

  公开（公告）日：2007-05-10

  The present invention provides a chemically stable and novel glycero-compound having one or two triple bonds, one molecule of a glycerol and one or two molecules of a fatty alcohol having a triple bond being linked through an ether bond, an organic group being linked to residual hydroxyl groups of the glycerol, which can be used as a membrane material for forming a vesicle membrane due to its high intermolecular cohesive force, and also provides a membrane forming material containing the same. The glycero-compound has a triple bond represented by the following general formula (1): wherein n and m each represents a number of 1 to 17 and the total (n+m) is a number of 4 to 18, n and m may be the same or different, and R represents a hydrogen atom, a metal atom, a phosphoric acid group, or an organic group which may be linked through a phosphoric acid group.

  本发明提供了一种化学稳定且新颖的甘油化合物，其中含有一个或两个三键，一个甘油分子和一个或两个含有三键的脂肪醇分子通过醚键连接，有机基与甘油的残余羟基连接，由于其高分子间内聚力可用作形成囊泡膜的膜材料，还提供了含有相同物质的膜形成材料。该甘油化合物具有以下一般式（1）所代表的三键：其中n和m分别表示1到17之间的数字，总数（n+m）为4到18之间的数字，n和m可以相同也可以不同，R表示氢原子、金属原子、磷酸基或可以通过磷酸基连接的有机基。
• GLMS RIBOSWITCHES, STRUCTURE-BASED COMPOUND DESIGN WITH GLMS RIBOSWITCHES, AND METHODS AND COMPOSITIONS FOR USE OF AND WITH GLMS RIBOSWITCHES
  申请人：Breaker Ronald R.

  公开号：US20100324123A1

  公开（公告）日：2010-12-23

  The glmS riboswitch is a target for antibiotics and other small molecule therapies. Compounds can be used to stimulate, active, inhibit and/or inactivate the glmS riboswitch. The atomic structures of the glmS riboswitch can be used to design new compounds to stimulate, active, inhibit and/or inactivate riboswitches.

  glmS核酸开关是抗生素和其他小分子治疗的靶点。化合物可以用于刺激、激活、抑制和/或失活glmS核酸开关。glmS核酸开关的原子结构可用于设计新的化合物，以刺激、激活、抑制和/或失活核酸开关。
• 13-Aza-14-oxo-txa2 analogues
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP0171146A1

  公开（公告）日：1986-02-12

  A novel 13-aza-14-oxo-TXA2 analogue of general formula: [wherein symbol A represents (i) a group of general formula: -CH2CH2-(CH2)m-, (ii)) a group of general formula: cis-CH=CH-(CH2)17, (iii) a group of general formula: -CH2O-(CH2)m-, (iv) a group of general formula: -S-(CH2)m-(wherein m represents an integer of from 1 to 6) or (v) a group of general formula: - R1 represents a hydrogen atom or a straight or branched alkyl group of from 1 to 12 carbon atom(s); R2 represents a bond or a straight or branched alkylene or alkylene group of from 1 to 10 carbon atom(s) unsubstituted or substituted by at least one of hydroxy group, amino group, halogen atom or phenylthio group; R3 represents (i) a phenyl, phenoxy or phenylthio group unsubstituted or substituted by at least one of straight or branched alkyl or alkoxy group of from 1 to 6 carbon atom(s), halogen atom or hydroxy group, (ii) a straight or branched alkyl, alkenyl or alkynyl group of from 1 to 6 carbon atom(s) unsubstituted or substituted by at least one of halogen atom or hydroxy group, (iii) a cycloalkyl, cycloalkyloxy or cycloalkylthio group of from 4 to 7 carbon atoms unsubstituted or substituted by at least one of straight or branched alkyl group of from 1 to 6 carbon atom(s), halogen atom or hydroxy group, (iv) a naphthyl, indolyl or indanyl group, or (v) an amino group unsubstituted or substituted by at least one of straight or branched alkyl group of from 1 to 6 carbon atom(s); and R4 represents a hydrogen atom or a methyl group. With proviso that, the carbon atom neighbored with R3 in R2 should have no substituents, when R3 represents a phenyloxy, phenylthio, cycloalkyloxy or cycloalkylthio group unsubstituted or substituted.] and cyclodextrin clathrates thereof and non-toxic salts thereof wherein R' represents a hydrogen atom possess an antagonistic activity on TXA2, in particular, inhibit blood platelet aggregation and contraction of artery, and are, therefore, useful for prevention and/or treatment of inflammation, hypertension, thrombus, cerebral apoplexy, asthma, cardiac infarction, angina pectoris, cerebral infarction and death by acute cardiac diseases in mammals, in particular in humans, which are induced by thromboxane A2.

  一种通式为 13-aza-14-oxo-TXA2 的新型类似物： [其中符号 A 代表 (i) 通式中的基团- -(CH2)m-、 (ii) 通式为：顺式-CH=CH-( )17 的基团、 (iii) 通式为- O-( )m-、 (iv) 通式为-S-( )m-(其中 m 代表 1 至 6 的整数)或 (v) 通式为- R1 代表氢原子或 1 至 12 个碳原子的直链或支链烷基； R2 代表未取代的或被羟基、氨基、卤素原子或苯硫基中的至少一个取代的键或 1 至 10 个碳原子的直链或支链亚烷基或亚烷基； R3 代表 (i) 未被 1 至 6 个碳原子的直链或支链烷基或烷氧基、卤素原子或羟基中的 至少一个取代的苯基、苯氧基或苯硫基、 (ii) 1 至 6 个碳原子的直链或支链烷基、烯基或炔基，未被卤素原子或羟基中的 至少一个取代或被取代、 (iii) 4 至 7 个碳原子的环烷基、环烷氧基或环烷基硫代基团，未被 1 至 6 个碳原子的直链或支链烷基、卤素原子或羟基中的至少一个取代或被其取代、 (iv) 萘基、吲哚基或茚基，或 (v) 未被取代或被至少一个 1 至 6 个碳原子的直链或支链烷基取代的氨基； 以及 R4 代表氢原子或甲基。 但 R3 代表未取代或取代的苯氧基、苯硫基、环烷氧基或环烷基硫基时，R2 中与 R3 相邻的碳原子应无取代基。］ 及其环糊精包合物和无毒盐，其中 R' 代表氢原子，具有拮抗 TXA2 的活性，特别是抑制血小板聚集和动脉收缩，因此、可用于预防和/或治疗由血栓素 A2 引起的哺乳动物，特别是人类的炎症、高血压、血栓、脑中风、哮喘、心肌梗塞、心绞痛、脑梗塞和急性心脏病引起的死亡。
• Novel sulfonamide derivatives
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP0312906A2

  公开（公告）日：1989-04-26

  A sulfonamide derivative of the general formula: wherein, R1 represents or wherein R11 represents a hydrogen atom, alkyl group of from 1 to 20 carbon atom(s), carbocyclic ring unsubstituted or substituted by an alkyl or alkoxy group of from 1 to 4 carbon atom(s) or halogen atom, or steroid, R12 represents a hydrogen atom or COR'S, R13 and R14 each represent a hydrogen atom or alkyl group of form 1 to 4 carbon atom(s) or NR13R14 represents an amino acid residue or heterocyclic ring, or R15 represetns an alkyl group of from 1 to 4 carbon atom(s) or phenyl group, represents or wherein represents Ba represents or wherein m represetns an integer of from 1 to 6, and the configuration of a double bond is E, Z or EZ and a phenylene group represetns and o-, m- or p-phenylene group in the formula (Ba-5), R2a represents a bond or an alkylene group of from 1 to 4 carbon atom(s), R3a represents a carbocyclic or heterocyclic ring unsubstituted or substituted by from one to three of an alkyl group of from 1 to 4 carbon atom(s), alkoxy group of from 1 to 4 carbon atom(s), hydroxy group, carboxyl group, ciano group, halogen atom or nitro group, or R2a represents an alkyl group of from 1 to 12 carbon atom(s) together with R3a, represents or Xb represents (i) bond, (ii) alkylene group of from to to 4 carbon atoms or (iii) alkenylene group of from 2 to 4 carbon atoms (with the proviso that α-CH=CHCH2β and αCH2CH=CHCH2β are exluded), R2b represents 3 (i) hydrogen atom, (ii) halogen atom or (iii) alkyl group of from 1 to 4 carbon atom(s), the configuration of a double bond between Cs and Cs in the general formula (B) is cis, represents or Lc represents an alkylene group of from 1 to 4 carbon atom(s). R2c represents a hydrogen atom, alkyl group of from 1 to 4 carbon atom(s) or halogen atom, the configuration of a double bond between Cs and Cs in the general formula (c) is cis or trans, with the proviso that when represents the general formula (A), R" doesn't reprsents a hydrogen atom or alkyl group of from 1 to 20 carbon atom(s); cyclodextrin clathrates thereof, or non-toxic salts thereof in case that R11 represents a hydrogen atom or NR13R14 represents an amino acid residue, possess an antagonistic activity on TXA2, in particular, inhibit blood platelet aggregation and contraction of artery, and are, therefore, useful for prevention and/or treatment of inflammation, hypertension, thrombus, cerebral apoplexy, asthma, cardiac infarction, angina pectoris, cerebral infarction and death by aucte cardiac diseases in mammales, in particular in humans, which are induced by thromboxane A2.

  通式如下的磺酰胺衍生物 其中，R1 代表 或 其中 R11 代表氢原子、1 至 20 个碳原子的烷基、未被或被 1 至 4 个碳原子的烷基或 烷氧基或卤素原子取代的碳环或甾族化合物、 R12 代表氢原子或 COR'S、 R13 和 R14 分别代表氢原子或 1 至 4 个碳原子的烷基，或 NR13R14 代表氨基酸残基或杂环，或 R15 代表 1 至 4 个碳原子的烷基或苯基、 代表 或 其中 代表 Ba 代表 或 其中 m 代表 1 至 6 的整数，双键的构型为 E、Z 或 EZ，苯基代表式 (Ba-5)中的邻苯基、间苯基或对苯基，R2a 代表键或 1 至 4 个碳原子的亚烷基、R3a 代表未被取代或被 1 至 3 个碳原子的烷基、1 至 4 个碳原子的烷氧基、羟基、羧基、氰基、卤素原子或硝基取代的碳环或杂环，或 R2a 与 R3a 一起代表 1 至 12 个碳原子的烷基、 代表 或 Xb 代表 (i) 键 (ii) 含至 4 个碳原子的亚烷基或 (iii) 2 至 4 个碳原子的烯基（但不包括 α-CH=CHCH2β 和 αCH2CH=CHCH2β ）、 R2b 代表 3 (i) 氢原子 (ii) 卤素原子或 (iii) 含 1 至 4 个碳原子的烷基、 通式（B）中 Cs 与 Cs 之间双键的构型为顺式、 代表 或 Lc 代表 1 至 4 个碳原子的亚烷基。R2c 代表氢原子、1 至 4 个碳原子的烷基或卤素原子、 通式（c）中 Cs 与 Cs 之间双键的构型为顺式或反式，但当 代表通式(A)时，R "不代表氢原子或 1 至 20 个碳原子的烷基； 在 R11 代表氢原子或 NR13R14 代表氨基酸残基的情况下，它们的环糊精凝块或无毒盐具有拮抗 TXA2 的活性，特别是抑制血小板聚集和动脉收缩，因此可用于预防和/或治疗心血管疾病、因此，可用于预防和/或治疗由血栓素 A2 引起的哺乳动物（尤其是人类）的炎症、高血压、血栓、脑中风、哮喘、心肌梗塞、心绞痛、脑梗塞和心脏病死亡。
• CHELATE-FORMING FILTER, PROCESS FOR PRODUCING THE SAME, AND METHOD OF PURIFYING LIQUID WITH THE FILTER
  申请人：Chelest Corporation

  公开号：EP1090668A1

  公开（公告）日：2001-04-11

  A chelate-forming filter having both the capability of capturing (removing), as a chelate, metals, metalloids or compounds thereof and the capability of removing insoluble impurities is disclosed, which is prepared by introducing a chelate-forming functional group represented by the following general formula (1) or (3) into a fiber molecule of a filter material made of a natural fiber, a regenerated fiber, or a synthetic fiber. A process for producing the same, and a process for the purification of a liquid using the filter are also disclosed.    [wherein, G represents a chain sugar alcohol residue or a polyhydric alcohol residue, and R represents a hydrogen atom, a (lower) alkyl group, or -G (wherein G has the same meaning as defined above and may be a group identical to or different from the aforementioned G)]    (wherein each of R1, R2, and R3 is a lower alkylene group, and n denotes an integer of 1 to 4).

  本发明公开了一种螯合型过滤器，它既能以螯合物的形式捕获（去除）金属、类金属或其化合物，又能去除不溶性杂质，其制备方法是在由天然纤维、再生纤维或合成纤维制成的过滤材料的纤维分子中引入下式（1）或（3）所代表的螯合官能团。此外，还公开了生产该过滤材料的工艺和使用该过滤材料净化液体的工艺。 [其中，G 代表链糖醇残基或多元醇残基，R 代表氢原子、（低级）烷基或 -G（其中 G 的含义与上述定义相同，可以是与上述 G 相同或不同的基团）]。 (其中 R1、R2 和 R3 各为低级亚烷基，n 表示 1 至 4 的整数）。